COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers

Journal of Neural Transmission

Volumn 103, Issue 6, 1996, Pages 729-736

  Keranen T ^b   Gordin, A ^a   Koulu, M ^c   Scheinin, M ^c   Antila, S ^a   Sundberg, S ^a   Wikberg, T ^a  

^a ORION CORPORATION   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

COMT inhibition; Entacapone; Growth hormone; Healthy volunteers; Levodopa; Prolactin

Indexed keywords

CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; ENTACAPONE; GROWTH HORMONE; LEVODOPA; PROLACTIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; CROSS-OVER STUDIES; DOPAMINE; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; HUMAN GROWTH HORMONE; HUMANS; LEVODOPA; MALE; PLACEBOS; PROLACTIN; TYROSINE;

EID: 0029827782     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01271232     Document Type: Article

References (23)

1. Bäckström R, Honkanen E, Pippuri A, et al (1989) Synthesis of some novel potent and selective catechol-O-methyltransferase inhibitors. J Med Chem 32: 841-846
2. Brown GM, Garfinkel PE, Warsh JJ, Stancer HC (1976) Effect of carbidopa on prolactin, growth hormone and cortisol secretion in man. J Clin Endocrinol Metab 43: 236-239
3. Camanni F, Massara F, Belferte L, et al (1977) Effects of dopamine on plasma growth hormone and prolactin levels in normal and acromegalic subjects. J Clin Endocrinol Metab 44: 465-473
4. Eddy RL, Jones AL, Chakmakjian ZH, Silverthorne MC (1971) Effect of levodopa (L-dopa) on human hypophyseal trophic hormone release. J Clin Endocrinol Metab 33: 709-712
5. Eisler T, Thorner MO, MacLeod RM, et al (1981) Prolactin secretion in Parkinson's disease. Neurology 31: 1356-1359
6. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd ed. Dekker, New York
7. Kaakkola S, Wurtman RJ (1992) Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study. Brain Res 587: 241-249
8. Kaakkola S, Gordin A, Männistö PT (1994) General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen Pharmacol 25: 813-824
9. Kaakkola S, Teräväinen H, Ahtila S, Rita H, Gordin A (1994) Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 44: 77-80
10. Keränen T, Gordin A, Harjola VP, et al (1993) The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 16: 145-156
11. Keränen T, Gordin A, Karlsson M, et al (1994) Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 46: 151-157
12. Koulu M, Lammintausta R (1981) Effects of L-Deprenyl on human growth hormone secretion. J Neural Transm 51: 223-231
13. Kytömäki O, Nousiainen R, Pekkarinen A, Rinne UK, Viljanen M (1973) Plasma growth hormone and insulin response to levodopa and amantadine. J Neural Transm 34: 145-151
14. Mars H, Genuth SM (1973) Potentiation of levodopa stimulation of human growth hormone by systemic decarboxylase inhibition. Clin Pharmacol Ther 14: 390-395
15. Masturzo P, De Maria A, Murialdo G, et al (1985) Benserazide effects on growth hormone, prolactin, and thyrotropin in normal and acromegalic men. J Clin Endocrinol Metab 61: 378-381
16. Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A (1994) Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 57: 186-189
17. Nissinen E, Lindén IB, Schultz E, Pohto P (1992) Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol 346: 262-266
18. Nutt JG, Woodward WR, Beckner RM, et al (1994) Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44: 913-919
19. Polleri A, Masturzo P, Murialdo G, Carolei A (1980) Dose and sex related effects of aromatic aminoacids decarboxylase inhibitors on serum prolactin in humans. Acta Endocrinol 93: 7-12
20. Ritschel WA (1986) Handbook of basic pharmacokinetics, 3rd ed. Drug Intelligence Publications, Illinois
21. Ruggieri S, Falaschi P, Baldassarre M, et al (1982) Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease. Neuropsychobiology 8: 102-108
22. Sundberg S, Scheinin M, Illi A, et al (1993) The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise. Br J Clin Pharmacol 36: 451-456
23. Wikberg T (1991) Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography. J Pharm Biomed Anal 9: 167-176